Alnylam Pharmaceuticals, Inc : Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Alnylam Pharma (ALNY) Announces Publication of Phase 1 Study Results for Zilebesiran streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran Acceptable Safety Profile Supporting Further Development